{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 57"},{"categories":[{"measurements":[{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 180"},{"categories":[{"measurements":[{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 360"}],"denomUnitsSelected":"Blood samples","denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"63"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"description":"Number of samples with a neutralizing response (defined as neutralization assay above 30%) will be reported. Participants would receive one to two vaccine boosters. Analysis of timepoints after booster 1 and booster 2 are reported collectively. Immunogenicity of mRNA-1273 vaccine was assessed for Booster Arm in participants with hematologic malignancy with or without ongoing immune suppression and participants with solid tumor receiving programmed death-1 (PD-1)/programmed death-ligand 1 inhibitor (PD-L1) inhibitors: Day 1, Day 29, Day 57, Day 180, and Day 360.","groups":[{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG000","title":"Chronic Lymphocytic Leukemia (CLL) Not on Active Therapy - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG001","title":"Chronic Lymphocytic Leukemia(CLL) Receiving Bruton´s Tyrosine Kinase(BTK) Interruption-Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG002","title":"Chimeric Antigen Receptor (CAR) T Cell Therapy - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG003","title":"Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG004","title":"Post Allogeneic Transplant - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on day 1.","id":"OG005","title":"Other Hematologic Malignancy - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG006","title":"Other Adult Solid Tumor - Booster Phase"}],"paramType":"NUMBER","populationDescription":"No participants were enrolled in Groups CLL, CLL/BTK, CAR-T Cell and Other Adult Solid Tumor Booster Phase. Regarding Other Hematologic Malignancy Booster Phase Group 1 participant crossed over from hematologic low immunosuppression-initial phase; 3 participants crossed over from hematologic intermediate immunosuppression-initial phase; 3 participants crossed over from hematologic high immunosuppression-initial phase; \\& 3 participants were initially enrolled (did not cross over) into this group.","reportingStatus":"POSTED","timeFrame":"Day 1, Day 29, Day 57, Day 180, and Day 360","title":"Number of Neutralizing Antibody Samples - Booster Phase","type":"SECONDARY","typeUnitsAnalyzed":"Blood samples","unitOfMeasure":"Samples"}